Biogen Aktie
| 155,70USD | -2,26USD | -1,43% |
WKN: 789617 / ISIN: US09062X1037
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,29 |
| The Vanguard Group, Inc. | 11,45 |
| PRIMECAP Management Co. | 11,20 |
| PRIMECAP Management Co. | 11,17 |
| Vanguard Group, Inc. (Subfiler) | 11,01 |
| Vanguard PRIMECAP Fund | 6,29 |
| SSgA Funds Management, Inc. | 5,04 |
| State Street Corp. | 5,04 |
| BlackRock Fund Advisors | 3,53 |
| Wellington Management Co. LLP (Wellington Breakout) | 3,43 |
| Vanguard Total Stock Market ETF | 3,17 |
| Vanguard Health Care Fund | 3,13 |
| T. Rowe Price Investment Management, Inc. | 2,92 |
| Vanguard 500 Index Fund | 2,62 |
| Geode Capital Management LLC | 2,48 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 7 400 | 9 100 | 9 610 | 8 725 | 7 570 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,72 | 1,36 | 1,08 | 1,08 | 1,24 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 8 382 | 6 887 | 7 857 | 9 791 | 6 859 |
| Summe Anlagevermögen | 18 853 | 17 732 | 16 021 | 14 763 | 19 986 |
| Summe Aktiva | 27 234 | 24 619 | 23 877 | 24 554 | 26 845 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 6 441 | 7 911 | 7 693 | 6 711 | 7 429 |
| Summe Fremdkapital | 13 895 | 13 933 | 12 918 | 11 166 | 12 045 |
| Summe Eigenkapital | 13 339 | 10 686 | 10 960 | 13 388 | 14 799 |
| Summe Passiva | 27 234 | 24 619 | 23 877 | 24 554 | 26 845 |
Adresse
| 225 Binney Street, 02142 Cambridge | |
| Telefon | +1 (617) 679-2000 |
| Internet | http://www.biogen.com |
Management
|
Adam Keeney
Executive VP & Head-Corporate Development |
|
Anabella Villalobos
SVP-Biotherapeutic & Medicinal Sciences |
|
Caroline D. Dorsa
Chairman |
|
Christopher A. Viehbacher
President, Chief Executive Officer & Director |
|
Chuck Triano
Head-Investor Relations |
|
Daniel Quirk
Chief Medical Officer & Head-Medical Affairs |
|
Eric K. Rowinsky
Independent Director |
|
Ginger Gregory
Chief Human Resources Officer & Executive VP |
|
Jake Elkins
Vice President & Head-Acute Neurology Research |
|
Jane Grogan
Executive Vice President & Head-Research |
|
Jesus B. Mantas
Independent Director |
|
Lloyd B. Minor
Director |
|
Maria C. Freire
Independent Director |
|
Menelas NICOLAS Pangalos
Director |
|
Michael E. Dambach
Treasurer & Vice President |
|
Michael Hencke
Executive Director-Investor Relations |
|
Michael R. McDonnell
Chief Financial Officer & Executive Vice President |
|
Monish Patolawala
Independent Director |
|
Nancy A. Simonian
Vice President-Medical Research & Development |
|
Nicole Murphy
Head-Pharmaceutical Operations & Technology |
|
Priya Singhal
Head-Development |
|
Rachid Izzar
Executive Vice President |
|
Robert Kilo
Account Director |
|
Robin C. Kramer
Chief Accounting Officer & Senior Vice President |
|
Stephen A. Sherwin
Independent Director |
|
Susan H. Alexander
Chief Legal Officer & Executive Vice President |
|
Susan Langer
Independent Director |
|
Tom Holmes
Senior Director-External Manufacturing |
|
Wendell C. Taylor
Secretary & Chief Counsel |
|
William A. Hawkins
Independent Director |
|
Xu Cheryl
Vice President-Public Policy & Government Affairs |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
